These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9706431)

  • 61. Hydroxychloroquine-Induced Reversible Hypomnesis in Systemic Lupus Erythematosus.
    Feng SW; Luo ZY; He XQ; Liu JH; Luo DQ
    J Clin Rheumatol; 2018 Aug; 24(5):291-293. PubMed ID: 29239937
    [No Abstract]   [Full Text] [Related]  

  • 62. [The everyday clinician. A wolf in sheep's clothing].
    Théophile
    Rev Med Brux; 2011; 32(5):490. PubMed ID: 22165530
    [No Abstract]   [Full Text] [Related]  

  • 63. Hydroxychloroquine: do we all see eye to eye? A single-site analysis of hydroxychloroquine dosing compared with the 2016 Revision of the American Academy of Ophthalmology guidelines.
    Sandhu VK; Goel N; Duro T
    Lupus; 2019 Mar; 28(3):438-439. PubMed ID: 30712492
    [No Abstract]   [Full Text] [Related]  

  • 64. Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.
    Cameron MC; Word AP; Dominguez A
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419748
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hydroxychloroquine-induced mimic of renal Fabry disease.
    Sperati CJ; Rosenberg AZ
    Kidney Int; 2018 Sep; 94(3):634. PubMed ID: 30143072
    [No Abstract]   [Full Text] [Related]  

  • 66. Hydroxychloroquine: a treatable cause of cardiomyopathy.
    Abbasi S; Tarter L; Farzaneh-Far R; Farzaneh-Far A
    J Am Coll Cardiol; 2012 Aug; 60(8):786. PubMed ID: 22898072
    [No Abstract]   [Full Text] [Related]  

  • 67. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
    Mititelu M; Wong BJ; Brenner M; Bryar PJ; Jampol LM; Fawzi AA
    JAMA Ophthalmol; 2013 Sep; 131(9):1187-97. PubMed ID: 23887202
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.
    Manohar VA; Moder KG; Edwards WD; Klarich K
    J Rheumatol; 2009 Feb; 36(2):440-1. PubMed ID: 19208570
    [No Abstract]   [Full Text] [Related]  

  • 70. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
    Aylward JM
    J Am Optom Assoc; 1993 Nov; 64(11):787-97. PubMed ID: 8120333
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Central variant of posterior reversible encephalopathy syndrome in systemic lupus erythematosus: new associations?
    Bag AK; Curé JK; Sullivan JC; Roberson GH
    Lupus; 2010 Feb; 19(2):225-6. PubMed ID: 19880556
    [No Abstract]   [Full Text] [Related]  

  • 72. Diagnostic and Therapeutic Challenges.
    Neamtu DV; Eller AW; Cohen SY
    Retina; 2016 May; 36(5):1039-44. PubMed ID: 26735561
    [No Abstract]   [Full Text] [Related]  

  • 73. Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate.
    Matsuda-Hirose H; Sho Y; Yamate T; Nakamura Y; Saito K; Takeo N; Nishida H; Ishii K; Sugiura K; Hatano Y
    J Dermatol; 2020 Feb; 47(2):e53-e54. PubMed ID: 31840277
    [No Abstract]   [Full Text] [Related]  

  • 74. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.
    Maturi RK; Yu M; Weleber RG
    Arch Ophthalmol; 2004 Jul; 122(7):973-81. PubMed ID: 15249360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Asymptomatic sensorineural hearing loss in patients with systemic lupus erythematosus.
    Roverano S; Cassano G; Paira S; Chiavarini J; Graf C; Rico L; Heredia C
    J Clin Rheumatol; 2006 Oct; 12(5):217-20. PubMed ID: 17023806
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
    Wozniacka A; McCauliffe DP
    Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sensorineural hearing loss in conjunction with aortic insufficiency in systemic lupus erythematosus.
    Peeva E; Barland P
    Scand J Rheumatol; 2001; 30(1):45-7. PubMed ID: 11252692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
    Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
    Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hydroxychloroquine in lupus pregnancy.
    Clowse ME; Magder L; Witter F; Petri M
    Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hydroxychloroquine-related hyperpigmentation.
    Muller R; Jarrot PA; Kaplanski G
    Rheumatology (Oxford); 2022 Feb; 61(2):873. PubMed ID: 33871581
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.